1-5 of 5
Huiling Zhen
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Deep and Durable Cytogenetic and Molecular Responses with Pemigatinib in Myeloid/Lymphoid Neoplasms with Fibroblast Growth Factor Receptor 1 Rearrangement: The Fight-203 Study

Andreas Reiter, Jean-Jacques Kiladjian, Jay L. Patel, William Shomali, Alessandro Rambaldi, Srdan Verstovsek, Stephen Oh, Kensuke Usuki, Claire N Harrison, Ellen K. Ritchie, Luke P. Akard, Juan Carlos Hernandez Boluda, Françoise Huguet, Natalia Oliveira, Huiling Zhen, Tracy I. George, Philomena Colucci, Aidan Gilmartin, Jason Gotlib, Alessandro M. Vannucchi
Journal: Blood
Blood (2023) 142 (Supplement 1): 4551.
https://doi.org/10.1182/blood-2023-180945
Published: 2023
Journal Articles

FIGHT-203, an Ongoing Phase 2 Study of Pemigatinib in Patients With Myeloid/Lymphoid Neoplasms (MLNs) With Fibroblast Growth Factor Receptor 1 ( FGFR1 ) Rearrangement (MLN FGFR1 ): A Focus on Centrally Reviewed Clinical and Cytogenetic Responses in Previously Treated Patients

Srdan Verstovsek, Jason Gotlib, Alessandro M. Vannucchi, Alessandro Rambaldi, Andreas Reiter, William Shomali, Tracy I. George, Jay L. Patel, Philomena Colucci, Huiling Zhen, Natalia Oliveira, Jean-Jacques Kiladjian
Journal: Blood
Blood (2022) 140 (Supplement 1): 3980–3982.
https://doi.org/10.1182/blood-2022-163099
Published: 2022
Journal Articles

A Phase 2 Study of Pemigatinib (FIGHT-203; INCB054828) in Patients with Myeloid/Lymphoid Neoplasms (MLNs) with Fibroblast Growth Factor Receptor 1 (FGFR1) Rearrangement (MLN FGFR1 )

Jason Gotlib, Jean-Jacques Kiladjian, Alessandro Vannucchi, Alessandro Rambaldi, Andreas Reiter, William Shomali, Tracy I. George, Jay L. Patel, Philomena Colucci, Chris Walker, Huiling Zhen, Srdan Verstovsek
Journal: Blood
Blood (2021) 138 (Supplement 1): 385.
https://doi.org/10.1182/blood-2021-148103
Published: 2021
Journal Articles

Interim Results from Fight-203, a Phase 2, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Pemigatinib (INCB054828) in Patients with Myeloid/Lymphoid Neoplasms with Rearrangement of Fibroblast Growth Factor Receptor 1 ( FGFR1 )

Srdan Verstovsek, MD PhD, Alessandro M. Vannucchi, MD, Alessandro Rambaldi, MD PhD, Jason R. Gotlib, MDMS, Adam J. Mead, MD PhD, Andreas Hochhaus, MD, Jean-Jacques Kiladjian, MD PhD, Juan Carlos Hernandez Boluda, MD PhD, Ekaterine Asatiani, MD, Christine Lihou, BS, Huiling Zhen, MD PhD, Andreas Reiter, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 690.
https://doi.org/10.1182/blood-2018-99-110388
Published: 2018
Journal Articles

Ruxolitinib for essential thrombocythemia refractory to or intolerant of hydroxyurea: long-term phase 2 study results

Clinical Trials & Observations
Srdan Verstovsek, Francesco Passamonti, Alessandro Rambaldi, Giovanni Barosi, Elisa Rumi, Elisabetta Gattoni, Lisa Pieri, Huiling Zhen, Muriel Granier, Albert Assad, Mario Cazzola, Hagop M. Kantarjian, Tiziano Barbui, Alessandro M. Vannucchi
Journal: Blood
Blood (2017) 130 (15): 1768–1771.
https://doi.org/10.1182/blood-2017-02-765032
Published: 2017
Includes: Supplemental data